MedTrace Logo

Treatment of Preterm Labor With 17 Alpha-hydroxyprogesterone Caproate

NCT00120640 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2012-09-19

No results posted yet for this study

Summary

The goal of our research will be to determine the effectiveness of 17 alpha-hydroxyprogesterone caproate (17P) in the treatment of preterm delivery. Treatment with progesterone is emerging as the standard of care for prevention of preterm delivery in asymptomatic patients at high risk for preterm birth due to a prior preterm delivery. Our goal is to evaluate whether or not progesterone is also effective in reducing preterm birth in symptomatic patients.

Conditions

  • Premature Birth
  • Premature Labor

Interventions

DRUG

17 hydroxyprogesterone caproate intramuscular injections

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Anna K Sfakianaki, MD · Yale University

  • Edmund F Funai, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00120640 on ClinicalTrials.gov